Efavirenz treatment causes arterial stiffening in apolipoprotein E-null mice

Journal of Biomechanics

Volumn 48, Issue 10, 2015, Pages 2176-2180

  Caulk, Alexander W ^a   Soler, Jose ^a   Platt, Manu O ^b   Gleason, Rudolph L ^a,b  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Arterial stiffening; Atherosclerosis; Efavirenz; HAART; Vascular remodeling

Indexed keywords

BLOOD VESSELS; DIAGNOSIS; DISEASE CONTROL; DISEASES; LIPOPROTEINS;

ARTERIAL STIFFENING; ATHEROSCLEROSIS; EFAVIRENZ; HAART; VASCULAR REMODELING;

MAMMALS;

EFAVIRENZ; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN E; BENZOXAZINE DERIVATIVE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL STIFFNESS; ARTERIAL WALL THICKENING; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIOMECHANICS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOLOGY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASCULAR REMODELING;

ANIMALS; ANTI-HIV AGENTS; AORTA, ABDOMINAL; AORTA, THORACIC; APOLIPOPROTEINS E; BENZOXAZINES; CAROTID INTIMA-MEDIA THICKNESS; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; MALE; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; VASCULAR REMODELING; VASCULAR STIFFNESS;

EID: 84937525921     PISSN: 00219290     EISSN: 18732380     Source Type: Journal    
DOI: 10.1016/j.jbiomech.2015.05.010     Document Type: Article

References (39)

1. Apostolova N., Gomez-Sucerquia L.J., et al. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br. J. Pharmacol. 2010, 160(8):2069-2084.
2. Back D.J., Owen A., et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin. Pharmacokinet. 2006, 45(2):214-215. 213-214; author reply.
3. Balani S.K., Kauffman L.R., et al. Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys. Drug Metab. Dispos. 1999, 27(1):41-45.
4. Blas-Garcia A., Apostolova N., et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010, 52(1):115-125.
5. Carr A., Samaras K., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353(9170):2093-2099.
6. Csajka C., Marzolini C., et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 2003, 73(1):20-30.
7. Dobrin P.B. Biaxial anisotropy of dog carotid artery: estimation of circumferential elastic modulus. J. Biomech. 1986, 19(5):351-358.
8. 2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 2007, 195(1):39-47.
9. Fontas E., van Leth F., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J. Infect. Dis. 2004, 189(6):1056-1074.
10. Friis-Moller N., Sabin C., et al. Combination antiretroviral therapy and the risk of myocardial infarction. New Engl. J. Med. 2003, 349(21):1993-2003.
11. Gleason R.L., Gray S.P., et al. A multiaxial computer-controlled organ culture and biomechanical device for mouse carotid arteries. J. Biomech. Eng. 2004, 126(6):787-795.
12. Gleason R.L., Caulk A.W., et al. Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in addis ababa, ethiopia. PLoS One 2015, 10(4):e0117125.
13. Gupta S.K., Shen C., et al. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One 2012, 7(9):e45716.
14. Han H.C. A biomechanical model of artery buckling. J. Biomech. 2007, 40(16):3672-3678.
15. Hansen L., Parker I., et al. Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice. J. Biomech. 2013, 46(9):1540-1547.
16. Hansen L., Parker I., et al. Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice. Ann. Biomed. Eng. 2013, 41(4):682-693.
17. Hsue P., Lo J., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004, 109(13):1603-1608.
18. Hsue P.Y., Hunt P.W., et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009, 23(15):2021-2027.
19. Jamaluddin M.S., Lin P.H., et al. Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis 2010, 208(1):104-111.
20. Jiang B., Khandelwal A.R., et al. Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. Toxicol. Sci. 2010, 117(2):524-536.
21. Laurent S., Boutouyrie P., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37(5):1236-1241.
22. Maggi P., Lillo A., et al. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004, 18(7):1023-1028.
23. Maiellaro-Rafferty K., Weiss D., et al. Catalase overexpression in aortic smooth muscle prevents pathological mechanical changes underlying abdominal aortic aneurysm formation. Am. J. Physiol. Heart Circ Physiol. 2011, 301(2):H355-H362.
24. Mary-Krause M., Cotte L., et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003, 17(17):2479-2486.
25. Mattace-Raso F.U., van der Cammen T.J., et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation 2006, 113(5):657-663.
26. Mukhamedova N., Rose H., et al. Antiretroviral compounds and cholesterol efflux from macrophages. Atherosclerosis 2009, 206(2):439-443.
27. Rachev A. A theoretical study of mechanical stability of arteries. J. Biomech. Eng. 2009, 131(5):051006.
28. Rosenfeld M.E., Polinsky P., et al. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 2000, 20(12):2587-2592.
29. Sevastianova K., Sutinen J., et al. Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy. Antivir. Ther. 2005, 10(8):925-935.
30. Shankar S., Dube M., et al. Indinavir impairs endothelial function in healthy HIV-negative men. Am. Heart J. 2005, 150(5):933.
31. Stein J., Klein M., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104(3):257-262.
32. Sutliff R.L., Dikalov S., et al. Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am. J. Physiol. Heart Circ. Physiol. 2002, 283(6):H2363-H2370.
33. Tohyama J., Billheimer J.T., et al. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Atherosclerosis 2009, 204(2):418-423.
34. van Leth F., Phanuphak P., et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004, 1(1):e19.
35. Van Loon P. Length-force and volume-pressure relationships of arteries. Biorheology 1977, 14(4):181-201.
36. van Vonderen M., Hassink E., et al. Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J. Infect. Dis. 2009, 199(8):1186-1194.
37. Wan W., Yanagisawa H., et al. Biomechanical and microstructural properties of common carotid arteries from fibulin-5 null mice. Ann. Biomed. Eng. 2010, 38(12):3605-3617.
38. Weber T., Auer J., et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004, 109(2):184-189.
39. Weibel J., Fields W.S. Tortuosity, coiling, and kinking of the internal carotid artery. II. Relationship of morphological variation to cerebrovascular insufficiency. Neurology 1965, 15:462-468.